Scientifically validated Infection Diagnostics with research and data backed results.
De-Risked technology achieved –
True Bearing has evolved from initial efforts to look at degenerative diseases from a systems biology or wholistic perspective. After starting a lab with lofty aspirations, we soon discovered that diagnostic development efforts were, on a generalized basis, essentially set up to fail. This has been proven true by the lack of pre-symptomatic Diagnostic development success across most of healthcare.
Back in 2006-7, We discovered the reason why. It is due, in short, to flawed target identification technologies mostly driven by amplification based genetic sequencing (NGS) approaches which, unfortunately, are still in play to this day. The large data sets being developed and saved for researchers to use in diagnostic development have an approximate 30% variance rate which translates to their being inaccurate for disease identification.
Knowing and understanding that flaw. we sought out and discovered a better, more accurate amplification free NGS technology, in 2009, purchased an instrument for $1M, converted ourselves into a non-profit organization and spent the following years in a de-risking effort for the sake of the future of healthcare. Through the non-profit, we financially and technologically enabled researchers around the globe to pursue their diagnostic target identification efforts with that same more accurate amplification free, NGS tool we had purchased and we tracked those researchers that we were partially funding. The result has allowed us to achieve a more advanced, more accurate approach to diagnostics as a culmination of our frugal investment of approximately $15M in non-dilutive funding between 2006 and 2024.
Following the derisking process we have spent years undertaking, we are pleased to offer True Bearing to the world of Healthcare. True Bearing is starting with abdominal infection and chronic abdominal pain as it will be the most efficient timeline to initial FDA Clearance and large scale commercialization potential.
True Bearing Diagnostics is the technology that emerged first from the groups we have supported as being tested, having engaged in clinical studies, creating data sets, being published, patented and proving itself ready for FDA Clearance and Commercialization in the infection diagnostic space. Once achieved, we intend to expand to the full spectrum of infection and then, to the broader diagnostics realm.
True Bearing is developing resilient technology which will advance the future of health care across a broad range of diseases including the significant unmet needs of abdominal pain.
True Bearing was incorporated in 2017 to extend and commercialize certain research breakthroughs developed by The St. Laurent Institute and The George Washington University’s Division of Genomic Medicine. The Company’s mission is to introduce a collection of RNA-based blood tests that will drastically decrease the costs associated with the early-detection and treatment of multiple diseases. True Bearing is currently developing biomarker panels that, it believes, will drastically improve the diagnosis of infection.
>90%
Accuracy Rate
$30B
Addressable Market
$5.1B
Abdominal Infection Market
10+
Patents and Publications
TruNAV
True Bearing Diagnostics has developed TruNAV, a novel RNA derived blood-based diagnostic test designed for the early detection of infections.
- TruNAV works by measuring specific RNA transcripts in whole blood that are associated with activation of the human immune system.
- TruNAV RNA transcript targets are highly sensitive to Neutrophil Activation by any pathogen, be it bacterial, viral, or biofilm based.
- TruNAV is unique in its ability to detect biofilm infections that cause appendicitis and other conditions.
- TruNAV has undergone multiple studies resulting in datasets, publications, and patents confirming scientific basis of the approach.
- TruNAV is poised to a multi-center FDA clinical study to confirm its utility with diagnosing the presence of internal infections in patients with abdominal pain.
- TruNAV provides the potential to also be useful with future pandemics or infections, like COVID19, because it can detect the presence of a pathogen even before it is fully identified, sequenced, and treatable.
True Bearing Diagnostics, Inc. (“True Bearing”) is developing TruNAV®, the world’s first highly accurate host-driven RNA blood-based diagnostic tool designed for infection detection (Figure 1). TruNAV will offer a pathogen-agnostic approach to diagnosing infection, selecting which basic type is involved (bacterial, viral, and/or biofilm), and measuring the infection’s magnitude for ease of tracking the effectiveness of therapies like antibiotics. Our initial focus will address the diagnosis of intra-abdominal infection (IAI).
CYBIS
In development with George Washington University.
TruCAD
Key statistics about Coronary Artery Disease (CAD)
• In about 50% of cases, a heart attack is the first sign of CAD.
• More than 1 million diagnostic catheterizations are performed annually in the U.S., costing $16 B/yr.
• At least 40% of catheterizations return a “normal” result, and thus, are unnecessary.
• About 9 million myocardial imaging tests are performed each year in the U.S. at a cost of > $1 billion.
• Roughly 60-70% of imaging tests return a normal result, thus, are also unnecessary.
• TruCAD development in 100 patients indicates 80% accuracy versus clinical standard of 54%.
Economics of TruCAD
• Total addressable market is approximately 10 million U.S. adults presenting with symptoms of CAD.
• Potential expansion into “at risk” adult health testing market is 8-10 times greater.
• The market will expand by multiples with worldwide use, especially in countries with limited access to sophisticated cardiac imaging systems.
• Unlike existing invasive or non-invasive cardiac imaging systems, TruCAD could be employed multiple times over the course of a patient’s treatment to monitor the disease process, and tailor various therapies.
